187 related articles for article (PubMed ID: 36527574)
1. High expression of CETN2 is associated with platinum resistance and poor prognosis in epithelial ovarian cancer.
Qiu PY; Deng XH; Li L
Clin Transl Oncol; 2023 May; 25(5):1340-1352. PubMed ID: 36527574
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of RIF1 Enhances Sensitivity to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) by Regulating Nucleotide Excision Repair (NER) Pathway.
Liu YB; Mei Y; Tian ZW; Long J; Luo CH; Zhou HH
Cell Physiol Biochem; 2018; 46(5):1971-1984. PubMed ID: 29719287
[TBL] [Abstract][Full Text] [Related]
3. Low expression of NCALD is associated with chemotherapy resistance and poor prognosis in epithelial ovarian cancer.
Feng LY; Li L
J Ovarian Res; 2020 Mar; 13(1):35. PubMed ID: 32228639
[TBL] [Abstract][Full Text] [Related]
4. Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism.
Leung D; Price ZK; Lokman NA; Wang W; Goonetilleke L; Kadife E; Oehler MK; Ricciardelli C; Kannourakis G; Ahmed N
J Transl Med; 2022 Dec; 20(1):556. PubMed ID: 36463238
[TBL] [Abstract][Full Text] [Related]
5. Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer.
Tian H; Yan L; Xiao-Fei L; Hai-Yan S; Juan C; Shan K
Clin Epigenetics; 2019 Oct; 11(1):153. PubMed ID: 31666131
[TBL] [Abstract][Full Text] [Related]
6. A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy.
Kang J; D'Andrea AD; Kozono D
J Natl Cancer Inst; 2012 May; 104(9):670-81. PubMed ID: 22505474
[TBL] [Abstract][Full Text] [Related]
7. [Identification and prognostic value of differentially expressed proteins of patients with platinum resistance epithelial ovarian cancer in serum].
Wu WJ; Wang Q; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2016 Jul; 51(7):515-23. PubMed ID: 27465871
[TBL] [Abstract][Full Text] [Related]
8. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
Dressman HK; Berchuck A; Chan G; Zhai J; Bild A; Sayer R; Cragun J; Clarke J; Whitaker RS; Li L; Gray J; Marks J; Ginsburg GS; Potti A; West M; Nevins JR; Lancaster JM
J Clin Oncol; 2007 Feb; 25(5):517-25. PubMed ID: 17290060
[TBL] [Abstract][Full Text] [Related]
9. Expression of resistance gene and prognosis of chemotherapy in primary epithelial ovarian cancer.
Yang F; Gao B; Chen W; Du E; Liang Y; Hu X; Yang X
Medicine (Baltimore); 2018 Oct; 97(41):e12364. PubMed ID: 30313031
[TBL] [Abstract][Full Text] [Related]
10. Platelet-Derived Growth Factor D Is a Prognostic Biomarker and Is Associated With Platinum Resistance in Epithelial Ovarian Cancer.
Zhang M; Liu T; Xia B; Yang C; Hou S; Xie W; Lou G
Int J Gynecol Cancer; 2018 Feb; 28(2):323-331. PubMed ID: 29240605
[TBL] [Abstract][Full Text] [Related]
11. DNA repair gene associated with clinical outcome of epithelial ovarian cancer treated with platinum-based chemotherapy.
Kang S; Sun HY; Zhou RM; Wang N; Hu P; Li Y
Asian Pac J Cancer Prev; 2013; 14(2):941-6. PubMed ID: 23621265
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional epigenetic regulation of Fkbp1/Pax9 genes is associated with impaired sensitivity to platinum treatment in ovarian cancer.
Soto JA; Rodríguez-Antolín C; Vera O; Pernía O; Esteban-Rodríguez I; Dolores Diestro M; Benitez J; Sánchez-Cabo F; Alvarez R; De Castro J; Ibanez de Cáceres I
Clin Epigenetics; 2021 Aug; 13(1):167. PubMed ID: 34454589
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of YES1 is associated with favorable prognosis and increased platinum-sensitivity in patients with epithelial ovarian cancer.
Zhou Y; Chen P; Huang Q; Wan T; Jiang Y; Jiang S; Yan S; Zheng M
Histol Histopathol; 2020 Jul; 35(7):721-728. PubMed ID: 31970720
[TBL] [Abstract][Full Text] [Related]
14. ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance.
Kuhlmann JD; Wimberger P; Bankfalvi A; Keller T; Schöler S; Aktas B; Buderath P; Hauch S; Otterbach F; Kimmig R; Kasimir-Bauer S
Clin Chem; 2014 Oct; 60(10):1282-9. PubMed ID: 25015375
[TBL] [Abstract][Full Text] [Related]
15. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
16. miR-211 facilitates platinum chemosensitivity by blocking the DNA damage response (DDR) in ovarian cancer.
Wang T; Hao D; Yang S; Ma J; Yang W; Zhu Y; Weng M; An X; Wang X; Li Y; Wu D; Tang J; Yang C; He Y; Zhang L; Jin X; Wang G; Li Z; Zheng T; Meng H; Feng Y; Li X
Cell Death Dis; 2019 Jun; 10(7):495. PubMed ID: 31235732
[TBL] [Abstract][Full Text] [Related]
17. Helicase POLQ-like (HELQ) as a novel indicator of platinum-based chemoresistance for epithelial ovarian cancer.
Long J; Zhu JY; Liu YB; Fu K; Tian Y; Li PY; Yang WQ; Yang SY; Yin JY; Yin G; Zhang Y
Gynecol Oncol; 2018 May; 149(2):341-349. PubMed ID: 29572031
[TBL] [Abstract][Full Text] [Related]
18. Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index.
Hetland TE; Kærn J; Skrede M; Sandstad B; Tropé C; Davidson B; Flørenes VA
Cancer Chemother Pharmacol; 2012 May; 69(5):1307-14. PubMed ID: 22302409
[TBL] [Abstract][Full Text] [Related]
19. HPIP expression predicts chemoresistance and poor clinical outcomes in patients with epithelial ovarian cancer.
Wang Y; Li M; Meng F; Lou G
Hum Pathol; 2017 Feb; 60():114-120. PubMed ID: 27818289
[TBL] [Abstract][Full Text] [Related]
20. High co-expression of SLC7A11 and GPX4 as a predictor of platinum resistance and poor prognosis in patients with epithelial ovarian cancer.
Wu X; Shen S; Qin J; Fei W; Fan F; Gu J; Shen T; Zhang T; Cheng X
BJOG; 2022 Nov; 129 Suppl 2(Suppl 2):40-49. PubMed ID: 36485069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
